ArticleCell proliferation2018

Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.

Yang Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.